Armbruster SD, et al. - Through a retrospective review that involved central pathology confirmed stage I or II uterine clear cell carcinoma (UCCC) treated and/or followed between 2000 and 2016 of cases with pure or mixed histology with >50% UCCC, the researchers assessed clinicopathologic factors and adjuvant treatment impacts on recurrence-free (RFS) and overall survival (OS) in early-stage UCCC. One hundred and twelve women were recruited. Most subjects had mixed UCCC and 39% had pure UCCC. The majority of subjects had stage IA UCCC in comparison to stage IB or stage II disease. Chemotherapy + radiation, brachytherapy, whole pelvic radiation, chemotherapy alone, and observation were adjuvant treatments that were involved. Recurrent disease was observed in 38 women. Age ≥70 and positive LVSI were correlated with shorter RFS. Median OS was estimated to be 9.8 years. Age ≥70 and positive LVSI were correlated with shorter OS. However, the adjuvant treatment type did not influence RFS or OS. Hence, for early-stage UCCC subjects, OS approached 10 years. Moreover, despite the treatment modality, women ≥70 years had worse PFS and OS, reflecting consideration of the quality of life implications when electing for adjuvant therapy.